Latest news with #EuronextParis
Business Wire
4 hours ago
- Business
- Business Wire
SFL Releases Its 2025 Interim Financial Report
PARIS--(BUSINESS WIRE)--Regulatory News: SFL (Paris:FLY) has published its Interim Financial Report for the six months ended 30 June 2025 and filed it with France's securities regulator, Autorité des Marchés Financiers (AMF). The document can be viewed at the SFL website, in the 'Publications' section under "Results". About SFL Referent in the prime segment of the Parisian commercial real estate market, Société Foncière Lyonnaise stands out for the quality of its property portfolio, which is valued at €7.7 billion and is focused on the Central Business District of Paris (# Edouard VII, Washington Plaza, etc.), and for the quality of its client portfolio, which is composed of prestigious companies. As France's oldest property company, SFL demonstrates year after year an unwavering commitment to its strategy focused on creating a high value in use for users and, ultimately, substantial appraisal values for its properties. With its sights firmly set on the future, SFL is committed to sustainable real estate with the aim of building the city of tomorrow and helping to reduce carbon emissions in its sector. Stock market: Euronext Paris Compartment A – Euronext Paris ISIN FR0000033409 – Bloomberg: FLY FP – Reuters: FLYP PA S&P rating: BBB+ stable outlook
Yahoo
6 days ago
- Business
- Yahoo
OSE Immunotherapeutics lance une Newsletter pour les investisseurs individuels
OSE Immunotherapeutics Launches Newsletter for Individual Shareholders NANTES, France, July 17, 2025, 6:30pm CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs, today launched the inaugural edition of its Newsletter, designed specifically for individual shareholders and investors in France and internationally. " This year, OSE Immunotherapeutics celebrates the 10th anniversary of its listing on Euronext Paris and we are delighted to introduce this new communication channel for our valued individual shareholders" said Fiona Olivier, Chief Corporate Affairs & Investor Relations Officer of OSE Immunotherapeutics. " Beyond providing updates on Company developments, the Newsletter gives us an opportunity to shine a spotlight on our teams and offer deeper insights into topics that are typically only touched on in press releases. It's also a way for us to express our appreciation for the continued trust and support of our investor community. " Published regularly in French and English, the Newsletter will be available in the 'Investors' section of the OSE Immunotherapeutics website. To subscribe to receive our Newsletters: ABOUT OSE IMMUNOTHERAPEUTICSOSE Immunotherapeutics is a biotech company dedicated to developing first-in-class assets in immuno-oncology (IO) and immuno-inflammation (I&I) that address the unmet patient needs of today and tomorrow. We partner with leading academic institutions and biopharmaceutical companies in our efforts to develop and bring to the market transformative medicines for people with serious diseases. OSE Immunotherapeutics is based between Nantes and Paris and is quoted on Euronext. Additional information about OSE Immunotherapeutics assets is available on the Company's website: Click and follow us on LinkedIn. Follow us on Fiona Dé France Contact Media: FP2COMFlorence Portejoiefportejoie@ 6 07 768 283 U.S. Contact Media:RooneyPartners LLCKate Barrettekbarrette@ 212 223 0561 Forward-looking statements This press release contains express or implied information and statements that might be deemed forward-looking information and statements in respect of OSE Immunotherapeutics. They do not constitute historical facts. These information and statements include financial projections that are based upon certain assumptions and assessments made by OSE Immunotherapeutics' management considering its experience and its perception of historical trends, current economic and industry conditions, expected future developments and other factors they believe to be appropriate. These forward-looking statements include statements typically using conditional and containing verbs such as 'expect', 'anticipate', 'believe', 'target', 'plan', or 'estimate', their declensions and conjugations and words of similar import. Although the OSE Immunotherapeutics management believes that the forward-looking statements and information are reasonable, the OSE Immunotherapeutics' shareholders and other investors are cautioned that the completion of such expectations is by nature subject to various risks, known or not, and uncertainties which are difficult to predict and generally beyond the control of OSE Immunotherapeutics. These risks could cause actual results and developments to differ materially from those expressed in or implied or projected by the forward-looking statements. These risks include those discussed or identified in the public filings made by OSE Immunotherapeutics with the AMF. Such forward-looking statements are not guarantees of future performance. This press release includes only summary information and should be read with the OSE Immunotherapeutics Universal Registration Document filed with the AMF on April 30, 2025, including the annual financial report for the fiscal year 2024, available on the OSE Immunotherapeutics' website. Other than as required by applicable law, OSE Immunotherapeutics issues this press release at the date hereof and does not undertake any obligation to update or revise the forward-looking information or statements. Attachment EN_250717_Newsletter_vfSign in to access your portfolio
Business Insider
16-07-2025
- Automotive
- Business Insider
Renault shares crash 17% after the automaker's profit warning
Renault shares crashed as much as 17% after the French automaker cut its guidance for the year. Late Tuesday, the company lowered its operating margin guidance for 2025 from at least 7% to 6.5%. On Wednesday, Renault's stock on the Euronext Paris exchange was down 16.3% at 34.79 euros at 10:00 a.m. local time, marking its steepest one-day drop since the start of the COVID-19 pandemic in 2020. Renault attributed the revised forecast to "the deterioration of the automotive market trends with an increasing commercial pressure" from competitors and a slowdown in the retail segment. The company is also aiming for a free cash flow between 1 billion to 1.5 billion euros, down from at least 2 billion euros previously. Separately, Renault announced the appointment of Duncan Minto as interim CEO, following the resignation of Luca de Meo last month. De Meo joined luxury group Kering. Renault is expected to report half-year earnings on July 31. The company's shares are down more than 25% this year.
Business Insider
16-07-2025
- Automotive
- Business Insider
Renault shares crash 17% after automaker cuts guidance
Renault shares crashed as much as 17% after the French automaker cut its guidance for the year. Late Tuesday, the company lowered its operating margin guidance for 2025 from at least 7% to 6.5%. On Wednesday, Renault's stock on the Euronext Paris exchange was down 16.3% at 34.79 euros at 10:00 a.m. local time, marking its steepest one-day drop since the start of the COVID-19 pandemic in 2020. Renault attributed the revised forecast to "the deterioration of the automotive market trends with an increasing commercial pressure" from competitors and a slowdown in the retail segment. The company is also aiming for a free cash flow between 1 billion to 1.5 billion euros, down from at least 2 billion euros previously. Separately, Renault announced the appointment of Duncan Minto as interim CEO, following the resignation of Luca de Meo last month. De Meo joined luxury group Kering. Renault is expected to report half-year earnings on July 31. The company's shares are down more than 25% this year.
Yahoo
09-07-2025
- Business
- Yahoo
Half-Year Statement on the Implementation of the Liquidity Contract as of June 30, 2025
HALF-YEAR STATEMENT ON THE IMPLEMENTATION OF THE LIQUIDITY CONTRACT AS OF JUNE 30, 2025 Bernin (Grenoble), France, July 9, 2025 – Soitec (Euronext Paris) announces that, under the liquidity contract entrusted to BNP Paribas on July 3, 2023, on the settlement date of June 30, 2025, the following resources appeared on the liquidity account: 72,325 Soitec shares, and €904,901 During the 1st semester of 2025, a total of: 231,383 shares were bought for €14,129,177 (i.e. 2,855 transactions). 208,969 shares were sold for €12,889,302 (i.e. 2,792 transactions). We remind you that: At the time of the previous half-yearly balance sheet, on the settlement date of December 31, 2024, the following resources appeared on the liquidity account: 51,394 Soitec shares, and €2,009,718 During the 2nd semester of 2024, a total of: 215,838 shares were bought for €19,591,223 (i.e. 3,775 transactions); 197,982 shares were sold for €17,859,326 (i.e. 3,174 transactions). On July 3, 2023, the day before the start of trading, the following resources appeared on the liquidity account: €8,000,000. Aggregate data for each trading day in the 1st semester of 2025 are given in the appendix to this press release. ***** Agenda Annual General Meeting: July 22, 2025. First-quarter 2025-2026 revenue: July 22, 2025, after market close. ***** About Soitec Soitec (Euronext - Tech Leaders), a world leader in innovative semiconductor materials, has been developing cutting-edge products delivering both technological performance and energy efficiency for over 30 years. From its global headquarters in France, Soitec is expanding internationally with its unique solutions, and generated sales of 0.9 billion Euros in fiscal year 2024-2025. Soitec occupies a key position in the semiconductor value chain, serving three main strategic markets: Mobile Communications, Automotive and Industrial, and Edge and Cloud AI. The company relies on the talent and diversity of more than 2,200 employees, representing 50 different nationalities, working at its sites in Europe, the United States and Asia. Nearly 4,300 patents have been registered by Soitec. Soitec, SmartSiC™ and Smart Cut™ are registered trademarks of Soitec. For more information: and follow us on LinkedIn and X: @Soitec_Official ***** Media Relations: media@ Investor Relations: investors@ Attachment Soitec - PR Interim report as of June 30, 2025 liquidity contractSign in to access your portfolio
